Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label extension study of PF-07868489 in adults with pulmonary arterial hypertension
CTR20254000Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-07868489 in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Started Nov 2025; status: terminated.
02
Drugs
PF-07868489
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20254000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254000.